Amarantus Bioscience Holdings Inc (AMBS)

[blackhawks]

Just how many CPS (clinical performance studies) will LymPro require and who will provide them?

Uh, let's see. More than one study will be required and nobody knows the names of the clinical sites. That last point is important because it delays/deters new speculations over the names of projected 'partners' for LymPro AD.

Amarantus is now in a position to embark on long-term stability controls of the assay to ensure commercially-acceptable reproducibility, as well as enter into agreements with leading clinical sites to obtain additional clinical performance data for LymPro.